Q3 2025 AddLife AB Earnings Call Transcript
Key Points
- AddLife AB (LTS:0REZ) reported a strong EBITDA improvement in both business areas, with organic and acquired EBITDA growth reaching 20%.
- The company achieved a currency-adjusted growth of 7%, with 6% organic growth and an additional 1% from acquisitions.
- Labtech experienced robust growth of 9% excluding currency effects, and Medtech saw a healthy demand with a 5% growth.
- The company successfully reached its net debt to EBITDA goal of being below 3%, allowing for increased acquisition activity.
- AddLife AB's EBITDA margin improved to 11.1%, up from 9.8% last year, supported by lower interest costs and strong cost control.
- There was a 3% negative impact on revenue and EBITDA growth due to revaluation of continued considerations and restructuring costs.
- The UK market showed weakness, particularly in capital sales, due to budget uncertainties and hesitancy around capital spending.
- Some companies within the group still have lower profitability, requiring ongoing improvement efforts.
- The Medtech segment experienced a decline in top-line growth due to the removal of certain products during portfolio updates.
- The company faced technical challenges that delayed the earnings call, indicating potential issues in communication infrastructure.
Good morning everyone, and warm welcome to the AddLife AB Third quarter report. As usual, we will take you through the numbers and description of what has happened in the company during the quarter. Then we will open up for a Q&A session, and after that, as usual, we encourage you to stay on for a few more minutes to see an interesting video from one of our companies. This time around is from Healthcare 21 Ireland, a very important piece of the puzzle as we are growing throughout Europe and an important platform acquisition. So let's get going with the highlights of the Third quarter. So the AddLife companies all had a good quarter in the Third quarter of 2025. We saw a strong EBITDA improvement in both business areas. We saw a healthy customer demand. Currency adjusted growth increased by 7%, 6% organic, and a nice addition of 1% from acquisitions. The growth in lab tech was really strong, 9% excluding currency effects, and on the Medtech side, a very healthy demand in spite of the fact that we are updating our product portfolio and we saw a little
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
